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construct validity including convergent and discriminant va-
lidity were analysed.  Results: Five of eight IPQS subscales 
were found to be internally reliable and all subscales dem-
onstrated high stability over time. Correlations with validity 
measures indicated that the subscales assess dimensions of 
a construct, which is distinct from psychopathology, depres-
sion, beliefs about medication and insight, except for the 
 Identity subscale which substantially overlapped with mea-
sures of insight.  Conclusions: The German version of the 
IPQS is an essentially reliable and valid measure of IP for 
 German-speaking people with a schizophrenia spectrum 
disorder. This may encourage its usage in further studies in-
vestigating the impact of subjective beliefs about mental 
health problems on outcome and recovery in schizophrenia. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Although there are a number of effective interventions 
for people with a diagnosis of schizophrenia, such as an-
tipsychotic medication, cognitive-behaviour therapy and 
family interventions  [1] , the outcomes with regard to 
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 Abstract 
 Background: Because the mere definition of insight from 
the therapist’s viewpoint may not be sufficient to identify 
treatment targets for adherence enhancement, we need as-
sessment strategies which are more sensitive to the patient’s 
perspective. Illness perception (IP), defined as the beliefs
a patient holds about his/her health problems, has been 
shown to affect coping in the context of a physical or mental 
illness, e.g. compliance behaviour. To assess IP in people di-
agnosed with schizophrenia, the Illness Perception Ques-
tionnaire for Schizophrenia (IPQS) was developed. The aim 
of the present study was to analyse the psychometric prop-
erties of the German version of the IPQS.  Sampling and 
Methods: The study sample consisted of 128 German-speak-
ing outpatients suffering from chronic schizophrenia or 
schizoaffective disorder. To achieve comparability with the 
validation of the English scale version, the same constructs 
were assessed: psychopathology, depression, and beliefs 
about medication. Furthermore, insight into one’s illness 
was assessed. Internal consistency, test-retest reliability and 
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symptoms, social and vocational functioning, and well-
ness vary  [2] . It is important to understand the causes for 
these variations in order to improve the situation for pa-
tients and their relatives.
 A factor shown to explain significant amount of out-
come variance in schizophrenia is non-compliance de-
fined as the extent to which a person’s behaviour corre-
sponds to the recommendations of a healthcare provider 
 [3] . Between 40 and 60% of patients with a schizophrenia 
spectrum disorder do not take their antipsychotic medi-
cation as prescribed  [4, 5] and 24% of individuals with 
psychosis do not ‘attend appointments as scheduled’  [6] . 
In examining the reasons for non-compliance, lack of in-
sight – defined as the unawareness of mental disorder, of 
symptoms, social consequences and need for treatment 
 [7] – has been identified as a main risk factor  [4, 8] . Even 
if the significance of insight for compliance has been well 
demonstrated, and many reliable and valid assessments 
have been developed  [9] , the concept has been criticized 
due to its implicit paternalistic attitude: insight reflects 
the extent to which individuals agree to the biomedical 
illness model of schizophrenia  [10] . 
 In consequence, it was proposed to take the individu-
al’s subjective perspective in the context of illness into 
account more strongly, and the concept of illness percep-
tion (IP) was introduced. IP is defined as the self-defini-
tion of health status influenced by illness-related experi-
ences in the past  [11] . Originally developed in the physical 
health area, IP has recently been applied to individuals 
with mental disorders  [12–15] , their relatives  [16] , and 
mental health practitioners  [17] . Crisp et al.  [18] found 
that patients think differently about specific diagnoses, 
indicating the need for distinct assessment methods of IP. 
Additionally, Kinderman et al.  [19] pointed out that while 
in the case of physical health problems, there may be a 
desire to identify a disease entity that can be diagnosed 
and separated from the sense of self, the distinction be-
tween the illness and the self in psychosis is often more 
blurred, making the creation of an illness model more 
difficult. In light of these arguments, Lobban et al.  [20] 
 adopted  the  Illness Perception Questionnaire (IPQ) and
its newer versions [Illness Perception Questionnaire-Re-
vised (IPQ-R), Brief Illness Perception Questionnaire 
(Brief IPQ);  21, 22 ], which were designed to assess IP in 
the context of physical health, to the special needs of pa-
tients with schizophrenia, resulting in  the Illness Percep-
tion Questionnaire for Schizophrenia (IPQS) . As with the 
IPQ and its newer versions, the IPQS is based on Leven-
thal et al.’s  [23]  self-regulation model which postulates 
two modes of illness representation: the first one is of a 
cognitive nature and encompasses beliefs about (1) the 
causes of the health problems, e.g. external agents includ-
ing bacteria, viruses, job stress; internal sensitivity such 
as genetic factors; and behavioural aspects such as drink-
ing alcohol or lack of sleep; (2) the identity of the health 
problems including symptoms and labels that define it; 
(3) the timeline (e.g. acute versus chronic); (4) the conse-
quences of the health problems on one’s life (e.g. social 
isolation, vocational difficulties or financial losses); and 
(5) the potential to control or cure the illness (e.g.
by treatment or one’s own behaviour). The second mode 
of illness representation is affective and includes direct 
emotional responses to health problems such as fear,
anger or despair which are not mediated by cognitive
appraisal  [20] . Both representation modes together are 
thought to determine a person’s reaction in the context of 
a health threat such as compliance behaviour as a kind of 
coping. In recognition of the essential role emotional dys-
regulation plays in mental illness, the consideration of 
both representation modes made the  self-regulation mod-
el the most adequate model to adopt to schizophrenia in 
comparison to other common health belief models in the 
physical area  [24] . The psychometric properties of the 
IPQS were demonstrated on a sample of English-speak-
ing inpatients  [20] . Primary evidence suggests that the IP 
assessed by the IPQS contributes to a better understand-
ing of the individual differences in behavioural and emo-
tional responses to schizophrenia which are not satisfac-
torily explained by differences in insight  [25] .
 Whereas the IPQ for physical illnesses has already 
been translated into German [ 26 ; http://www.uib.no/ipq/
index.html], to the best of our knowledge, the IPQS has 
not. In order to use the IPQS in our research into the sub-
jective factors influencing compliance and recovery in 
chronic schizophrenia, we translated the scale into Ger-
man. The aim of the present study was to establish the 
psychometric properties of the German version, includ-
ing internal consistency, test-retest reliability and con-
struct validity, on a sample of outpatients. To achieve 
comparability with the validation of the English scale 
version  [20] , we assessed the same constructs as the orig-
inal authors, and expected the IPQS subscales to correlate 
with measures of symptoms, depression and attitudes to-
ward medication on a low level (r  ! 0.40), indicating that 
the IPQS assesses a distinct construct [discriminant va-
lidity;  27 ]. To the best of our knowledge, the associations 
of the IPQS subscales with measures of insight have not 
yet been examined. This is surprising given the fact that 
the  Identity  subscale assesses awareness and attribution 
of symptoms – two main components of the insight con-
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 2
:5
4:
15
 P
M
 IPQS Validation in Outpatients with 
Chronic Schizophrenia 
Psychopathology 2012;45:259–269 261
struct  [7] . Therefore, we intended to investigate the asso-
ciations between the IPQS subscales and measures of in-
sight and hypothesized strong correlations (r  1 0.70) with 
 Identity , indicating a high overlap of this dimension of IP 
with the insight construct [convergent validity;  27 ]. Be-
cause subjective and objective ratings of symptoms  [28] , 
depression  [29] , and insight  [9] do not necessarily corre-
late with each other, we assessed each construct by both 
a patient-rated measure and a clinician-rated one, facili-
tating the separate analysis of their associations with the 
IPQS subscales.
 Methods 
 Recruitment and Procedure 
 The recruitment took place at two community mental health 
services in Basel, Switzerland, between February 2009 and March 
2010. All patients between 18 and 65 years of age and diagnosed 
with schizophrenia or schizoaffective disorder were asked for 
study participation. Exclusion criteria were a primary diagnosis 
of alcohol or substance dependency, an organic syndrome or 
learning disability, inadequate command of German and home-
lessness. Of the 236 individuals screened for participation, 144 
(61.02%) provided written informed consent after a full explana-
tion of the study aims and procedures. The main reasons of re-
fusal were suspiciousness (n = 33, 35.9%), no interest (n = 15, 
16.3%) and fear of excessive demands or overwhelming emotions 
(n = 15, 16.3%). All assessments including interviews and ques-
tionnaires were conducted by three research psychologists who 
underwent assessment training before the beginning of the study. 
Diagnoses were confirmed by the Structured Clinical Interview 
for Diagnostic and Statistical Manual of Mental Disorders – IV 
Axis I Disorders  [30] . To avoid biases due to attention or motiva-
tion decline during the assessment, the presentation order of 
questionnaires was varied at random. Participants received a fi-
nancial compensation of 40 CHF in order to minimise selection 
bias by a high refuser rate. 128 participants (88.89%) completed 
the assessment. Their data were used in the present study. 64 
(50%) completers agreed to fill out the questionnaires twice with-
in a month for the purpose of test-retest reliability. They received 
an additional financial compensation of 50 CHF. The study was 
approved by the local ethics committee.
 Measurements 
 The Illness Perception Questionnaire for Schizophrenia 
(IPQS) 
 The IPQS consists of 131 items which are rated on a 5-point 
Likert scale (1 = ‘strongly disagree’ to 5 = ‘strongly agree’) and is 
comprised of ten subscales:
 •  Identity  (8 items): Originally, this subscale included 58 symp-
toms common in schizophrenia and schizoaffective disorder 
which were not further specified by the authors. The patients 
were asked to indicate which symptoms they experienced and 
to attribute them as due to ‘mental health problems’, ‘side ef-
fects of my medication’, and/or ‘other factors’. Finally, the pro-
portion of experiences attributed to each was calculated  [20] . 
In order to reduce patient burden, we used – in contrast to the 
English version – eight symptoms of the Positive and Negative 
Syndrome Scale (PANSS) which were also assessed by the 
Scale to Assess Unawareness of Mental Disorder (SUMD): hal-
lucinatory behaviour, delusions, conceptual disorganization, 
poor impulse control, lack of spontaneity and flow of conver-
sation, blunted affect, poor attention, and few social contacts 
due to passive-apathetic withdrawal or anxious avoidance. 
This strategy guaranteed that participants were only asked to 
consider symptoms which were objectively present. If a symp-
tom was judged to be present at the beginning of the study, as 
indicated by a PANSS score of 2 or above, patients were asked 
to indicate (1) whether they were aware of it (1 = ‘strongly’ to 
5 = ‘not at all’), and if so (indicated by a score of 3 or lower), (2) 
whether they attributed it to mental health problems. We then 
calculated the relative proportion of experiences, which pa-
tients were aware of and attributed to mental health problems. 
 •  Cause (26 items): A high item score denotes a high attribution 
of a cause to mental health problems, e.g. ‘Chemical imbalance 
in the brain’, ‘My personality’, ‘Hereditary; it runs in my fam-
ily’, ‘Money worries’, ‘Pollution in the environment’, ‘Alcohol’, 
‘My upbringing’, ‘Thinking about things too much’ or ‘Some-
one spiked my drink with illicit drugs’. No subscale score was 
calculated. 
 •  Timeline Acute/Chronic (6 items) and  Timeline Cyclical (4 
items): High scores denote a chronic and cyclical timeline of 
the mental health problems, respectively, e.g. ‘I expect to have 
these mental health problems for the rest of my life’ ( Timeline 
Acute/Chronic ) or ‘Sometimes I have more symptoms than 
other times’ ( Timeline Cyclical ). 
 •  Consequences  (11 items): A high subscale score denotes a per-
ception of a high level of negative impact of the mental health 
problems on work, important relationships, family, social life, 
everyday functioning, and the perception of one’s own inter-
personal attractiveness, e.g. ‘I have lost important relation-
ships as a result of my mental health problems’. The subscale 
additionally includes an item assessing positive effects (‘My 
mental health problems have had some positive effects on my 
life’; reversely scored). 
 •  Personal Control (4 items): A high score denotes a high degree 
of perceived personal control over the mental health problems, 
e.g. ‘There are some things that I can do to control my symp-
toms’. 
 •  Personal Blame (3 items): A high score denotes a high degree 
of self-blame for the mental health problems, e.g. ‘If I tried 
harder, I could control my symptoms’. 
 •  Treatment Control (5 items): A high score denotes a belief that 
treatment will be helpful in managing mental health prob-
lems, e.g. ‘My treatment can control my mental health prob-
lems’. 
 •  Illness Coherence (5 items): A high score denotes a sense of not 
having a coherent understanding of the mental health prob-
lems, e.g. ‘I don’t have any understanding of my mental health 
problems at all’.  
 •  Emotional Representation (9 items): A high score denotes a 
strong negative emotional response to the mental health prob-
lems, e.g. ‘I get depressed when I think about my mental 
health’. 
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 All subscales – except for  Personal Control and  Personal
Blame – demonstrated acceptable levels of internal consistency (  
 1 0.70) and high stability over time  [20] .
 We used Lobban et al.’s  [20] IPQS and translated it into Ger-
man. For cross-cultural research, semantic and content equiva-
lence are needed. To establish semantic equivalence of the Ger-
man version of the IPQS, a back-translation method was used. 
After the original version was translated into German, a bilingual 
PhD student translated the German version back into English 
without referring to the original English instrument, in accor-
dance with the recommended procedure for translating research 
instruments  [31] . Next, we compared the original English version 
with the German back-translation version and developed the final 
version by consensus. For content equivalence, the bilingual PhD 
student evaluated the content of each item. All items were found 
to be relevant for IP. The German version of the instrument is 
available upon request from the corresponding author.
 The Positive and Negative Syndrome Scale (PANSS)  
 The PANSS is a semi-structured interview to assess positive 
and negative symptoms as well as general psychopathology com-
mon in schizophrenia. In our study, their occurrence during the 
last seven days was evaluated. The 30 items are rated on a 7-point 
Li kert scale (1 = ‘absent’ to 7 = ‘extreme’) with higher scores indi-
cating higher levels of psychopathology. By summing up single 
items, the three subscales  Positive Syndrome (7 items),  Negative 
Syndrome (7 items), and  General Psychopathology (16 items) are 
formed  [32] . The measure was shown to be reliable with Cron-
bach’s   coefficients of 0.73 for the  Positive Syndrome Scale , of
0.83 for the  Negative Syndrome Scale , and of 0.79 for the  General 
Psychopathology Scale . For the German version of the PANSS, an 
inter-rater reliability of 80% was demonstrated after a standard-
ized rater training  [33] .
 The Subjective Well-Being under Neuroleptic Treatment 
Scale – Short Form (SWN-K) 
 The SWN is a self-report instrument to evaluate subjective well-
being under antipsychotic treatment with regard to the previous 
seven days. We used the short form consisting of 20 items and five 
subscales Mental Functioning (e.g. ‘I find it easy to think’),  Self-
Control (e.g. ‘I feel powerless and not in control of myself ’),  Emo-
tional Regulation (e.g. ‘I have no hope for the future’),  Physical 
Functioning (e.g. ‘My body feels familiar’), and  Social Integration 
(e.g. ‘I find it easy to keep in touch with people around me’). Pa-
tients are asked to rate their responses on a 6-point Likert scale (1 
= ‘not at all’ to 6 = ‘very much’). In our study we used only the total 
score with higher scores indicating a better subjective well-being 
during antipsychotic treatment. Based on data of a German sam-
ple, the short version was shown to correlate highly with the origi-
nal scale indicating good construct validity and to be highly reli-
able with a Cronbach’s   coefficient for the total score of 0.92  [34] .
 The Calgary Depression Scale for Schizophrenia (CDSS) 
 The CDSS is a semi-structured interview which was specifi-
cally developed to assess depression separately from negative 
symptoms in schizophrenia. It consists of eight questions and one 
interviewer observation which are all rated on a 4-point Likert 
scale (0 = ‘absent’ to 3 = ‘severe’). By summing up single items, a 
total score is built with a higher score indicating a higher level of 
depression. Construct validity was confirmed with other well-
established measures of depression. Reliability of the German ver-
sion has been demonstrated with an intra-class correlation coef-
ficient (ICC) of 0.70  [35] .
 The Beck Depression Inventory-Revised (BDI-II) 
 The BDI-II is a self-report instrument to assess the intensity of 
depressive symptoms in persons with and without a clinical diag-
nosis of depression. It consists of 21 items, each with four state-
ments indicating increasing severity (4-point Likert scale from 0 
to 3). For example: ‘In the past two weeks including today: I do not 
feel sad’, ‘I feel sad much of the time’, ‘I am sad all the time’, ‘I am 
so sad or unhappy that I cannot tolerate it’. By summing up single 
items, a total score is achieved ranging from 0 to 63. Validity and 
reliability (internal consistency:  6 0.84; test-retest reliability: 
 6 0.75) of the German version of the BDI-II were established in 
clinical and non-clinical samples  [36] .
 The Scale to Assess Unawareness of Mental Disorder 
(SUMD) 
 The SUMD is a semi-structured interview to evaluate global 
insight into illness and specific insight into symptoms with regard 
to the present and the past  [37] . The instrument design allows for 
the independent usage of any subscale depending on the goal of 
the investigation. In our study, we used the three non-symptom-
atic summary items assessing (1) global awareness of mental dis-
order, (2) awareness of the achieved effects of medication, and (3) 
awareness of the social consequences of having a mental disorder 
with regard to the present (defined as the past 7 days). The items 
are rated on a 5-point Likert scale (1 = ‘aware’ to 5 = ‘unaware’) 
with higher scores indicating poorer awareness. For the original 
English scale version, ICCs for the three summary items of 0.89, 
0.75, and 0.68 were reported  [37] .
 The Insight Scale (IS) 
 The IS is a self-report questionnaire to measure insight into 
psychiatric illness and treatment. The instrument contains eight 
statements to which the patient responds with ‘I agree’, ‘I dis-
agree’, or ‘I am unsure’. The items form the three subscales  Re-
labelling Symptoms (e.g. ‘Some of the symptoms were made by my 
mind’),  Awareness of Illness (e.g. ‘I am mentally well’), and  Need 
for Treatment (e.g. ‘I do not need medication’). Each subscore can 
reach a maximum of 4 with higher scores representing greater 
extent of insight. By summing up single items, a total score with 
a maximum of 12 indicating full insight is achieved. In our anal-
yses, we used the total score. This was found to have a Cronbach’s 
  coefficient of 0.75 and a test-retest reliability coefficient of 0.90 
in an English-speaking sample  [38] .
 The Beliefs about Medicines Questionnaire (BMQ) 
 The BMQ is an 18-item questionnaire measuring patients’
attitudes towards medication. It comprises two sections: (1) The 
BMQ Specific is a 10-item scale which assesses patients’ percep-
tions of their prescribed medication. Five items form the  Specific 
Necessity subscale (e.g. ‘My medicines protect me from becoming 
worse’), and five items the  Specific Concerns subscale (e.g. ‘I some-
times worry about the long-term effect of my medicines’). (2) The 
BMQ General is an 8-item scale, which assesses more general be-
liefs about medication. Four items build the  General Harm sub-
scale (e.g. ‘Doctors place too much trust on medicines’), and four 
items the  General Overuse subscale (e.g. ‘Most medicines are ad-
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dictive’). Each item is rated on a 5-point Likert scale (1 = ‘strong-
ly disagree’ to 5 = ‘strongly agree’). By summing up single items, 
the four subscale scores are achieved with higher scores indicating 
a stronger endorsement of the construct being measured. For the 
four subscales of the original English version, internal consisten-
cies ranging from   = 63 to 0.74 were reported  [39, 40] . 
 Statistical Analyses 
 In order to examine if the test-retest subsample differed from 
the other study participants regarding socio-demographic and 
clinical characteristics, we used t tests for continuous variables 
and   2 tests for categorical variables.
 With regard to reliability, internal consistency was calculated 
for all subscales with the exception of  Identity and  Cause  because 
these subscales were not designed to assess a coherent dimension 
 [20] . The subscales were classified as internally consistent if the 
Cronbach’s   coefficients exceeded 0.70  [41] . Additionally, Spear-
man’s correlations (r s ) between the items within each subscale and 
Pearson’s correlations (r) between the subscales were calculated. 
The non-parametric correlation was used due to the non-normal 
distribution of single items. To ensure that the items of a subscale 
assess the same dimension of the construct but are not redundant, 
correlation coefficients between 0.20 and 0.40 are recommended 
 [42, 43] . Regarding the inter-subscale correlations, coefficients 
should not exceed 0.70, denoting that the subscales assess differ-
ent construct dimensions  [27] . Test-retest reliability was analysed 
using Pearson’s correlations for associations between the scores at 
each time point, and t tests for differences between them. It was 
not possible to analyse test-retest reliability of the Identity sub-
scale because awareness and attribution of symptoms were esti-
mated only once at the beginning of the study in the context of the 
PANSS interview. Significant correlation coefficients were inter-
preted in terms of effect sizes as follows: r  ! 0.10 as small, r = 0.30 
as moderate, and r  1 0.50 as high  [44] .
 With regard to construct validity, Pearson’s correlations be-
tween the IPQS subscales and the measures of symptom severity, 
depression, beliefs about medication and insight were evaluated. 
Correlation coefficients  ^  0.40 were considered as indicators of 
discriminant validity, i.e. the instruments compared assess differ-
ent constructs  [27] . Correlation coefficients  6 0.70 were judged as 
indicators of convergent validity, i.e. the instruments compared 
assessed the same construct  [27] . The validity measures with sig-
nificant correlations were then used as independent variables for 
multiple regression analyses to determine if the relationships with 
the IPQS subscales persisted after simultaneous adjustment.
 All data analyses were performed using the Statistical Package 
for the Social Sciences Windows, Version 17.0 (SPSS Inc., Chicago, 
Ill., USA). If not otherwise specified, an   level of 0.05 was applied 
to define significance.
 Results 
 Sample Characteristics 
 Of the 128 participants, 41 (32%) were female. The 
mean age was 44.31 years (SD = 11.78). The majority of 
participants lived alone (n = 69; 53.9%) and had neither a 
stable partnership – defined as lasting three months or 
longer (n = 103; 80.5%) – nor children (n = 96; 75%). The 
mean years of education were 12.23 (SD = 2.87). Consid-
ering that nine years of education are obligatory in Swit-
zerland, the sample may be judged as poorly educated. 
With regard to the vocational situation, a minority of par-
ticipants (n = 8; 14.1%) had paid work; the remainder was 
in sheltered employment (n = 41; 32.1%) or without any 
employment (n = 69; 53.9%). As a consequence, the vast 
majority of participants (n = 103; 80.5%) received a gov-
ernmental disability annuity. 90 participants (70.3%) were 
diagnosed with schizophrenia and 38 (29.7%) with 
schizoaffective disorder. The mean illness duration was 
17.83 years (SD = 11.59). On average, participants had 
been hospitalized 8.45 times (SD = 11.45) and had received 
7.54 years (SD = 6.40) of outpatient treatment. The major-
ity (n = 120; 93.8%) were treated with antipsychotics: 113 
patients (88.3%) with at least one atypical medicine, one 
patient (0.8%) with a typical medicine, and six patients 
(4.75%) with a combination of an atypical medicine with 
a typical one.
 The test-retest subsample (n = 64; 50%) did not differ 
from the other study participants regarding socio-demo-
graphic and clinical characteristics with the single excep-
tion of parenthood: participants of the test-retest sub-
sample had significantly fewer children (15.63 vs. 34.38%; 
p = 0.014).
 IPQS: Descriptive Statistics 
 Regarding the  Cause subscale, ‘stress or worry’ were 
judged by a majority of participants (n = 47; 36.7%) as an 
important reason for the onset of their mental health prob-
lems (mode = 5; range of possible scorers: 1–5, with higher 
scores indicating stronger agreement). ‘Chance or bad 
luck’, ‘my family’s behaviour’, ‘family problems’, ‘thinking 
about things too much’, and ‘my own behaviour’ were 
mostly (n = 40–54; 31.3–42.2%) regarded as partly relevant 
(mode = 3) for the development of mental health problems. 
All other reasons (e.g. ‘a germ or virus’, ‘my personality’, 
‘lack of friends or people who care about me’, ‘hereditary; 
it runs in my family’, ‘overwork’, ‘taking illicit drugs’, 
‘chemical imbalance in the brain’) were appraised by the 
majority (n = 33–100; 25.8–77.3%) as irrelevant for the on-
set of their mental health problems (mode = 1).
 Means and standard deviations of all other subscales 
are shown in  table 1 .
 IPQS: Reliability 
 Internal Consistency 
 While  Timeline Acute/Chronic ,  Consequences ,  Treat-
ment Control and  Emotional Representation met the crit-
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ical value of    1 0.70 for internal consistency (see  table 1 ), 
 Timeline Cyclical (  = 0.67),  Personal Control (  = 0.52), 
 Personal Blame (  = 0.51) and  Illness Coherence (  = 0.48) 
failed to reach it. Given that  Timeline Cyclical contains 
only four items, which is likely to reduce internal consis-
tency, the   score of 0.67 may be judged as acceptable. 
However, the subscales assessing personal control, per-
sonal blame and illness coherence failed to reach reliabil-
ity.
 Inter-Item Correlations 
 The correlations between the items within the sub-
scales ranged between r s = 0.24 and r s = 0.40 (see  table 1 ), 
indicating that they assess the same dimension of the 
construct but are not redundant. There were two excep-
tions,  Illness Coherence (r s = 0.18) and  Timeline Acute/
Chronic (r s = 0.41), which both deviated just marginally 
from the recommended range for inter-item correlations 
between 0.20 and 0.40  [42, 43] . 
 Inter-Subscale Correlations 
 We found significant correlations among the IPQS 
subscales which ranged from r = 0.22 to r = 0.67 ( table 2 ). 
This indicates that the subscales assess dimensions of IP 
which are not redundant [r  ! 0.70;  27] .
 Test-Retest Reliability 
 The subscales showed highly positive correlations over 
the test-retest period which ranged from r = 0.49 to r = 
0.73 ( table 3 ). This indicates a strong association between 
the two assessment points  [44] . Additionally, no signifi-
cant differences were found between the scores assessed 
at the two time points.
 IPQS: Construct Validity 
 The Pearson’s correlation coefficients between the 
IPQS subscales and the validity measures are presented 
in  table 4 .
 The significant correlation coefficients between the 
IPQS subscales and the validity measures ranged from
r = 0.18 to r = 0.63, indicating a moderate to high rela-
tionship between the IP dimensions and symptom se-
verity, depression, insight and beliefs about medication 
 [44] . None of the found correlation coefficients exceed-
ed the critical value for convergent validity (r  1 0.70), 
denoting that the validity measures (PANSS, SWNK, 
CDSS, BDI-II, SUMD, IS, BMQ) do not assess the same 
construct as the IPQS. Moreover, most correlation coef-
ficients lay below the critical value for discriminant va-
lidity (r  ! 0.40), indicating that the instruments com-
pared assess different constructs  [27] . However, there 
were some exceptions with correlation coefficients be-
tween 0.40 and 0.70, suggesting a certain overlap be-
tween the constructs assessed: the subjective measure of 
psychopathology (SWN-K total score) with  Conse-
quences (r = –0.62),  Illness Coherence (r = –0.46) and 
 Emotional Representation (r = –0.63); the subjective 
measure of depression (BDI-II) with  Consequences (r = 
Table 1.  Mean scores, mean inter-item correlations and Cronbach’s  coefficients for the IPQS subscales
IPQS subscale (n = 128) Number
of items
Mean 8 SDa Mean inter-item
correlationb

Identityc
Symptom awareness (n = 110)
Symptom attribution (n = 92)
8
8
2.2681.38
2.8381.48
–
–
–
–
Timeline acute/chronic 6 3.3080.08 0.41 0.81
Timeline cyclical 4 3.6780.07 0.35 0.67
Consequences 11 3.1080.06 0.24 0.76
Personal control 4 3.4980.07 0.24 0.52
Personal blame 3 2.7480.09 0.26 0.51
Treatment control 5 3.9580.07 0.40 0.74
Illness coherenced 5 2.4080.06 0.18 0.48
Emotional representation 9 2.7980.08 0.38 0.85
a  Range of possible scores: 1–5 with a higher score indicating higher parameter value.
b Spearman’s correlation (rs).
c Range of possible scores: 1–5 with a higher score indicating lower awareness and attribution.
d Higher scores denote less coherent understanding of the mental health problems.
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0.45) and  Emotional Representation (r = 0.47); the
measures of insight (IS, SUMD) with  Identity 
(r = –0.41 to 0.61) and  Timeline Acute/Chronic (r = 0.47); 
and the measures of beliefs about medication with  Con-
sequences (r = 0.53),  Treatment Control (r = –0.44 to 
–0.52) and  Emotional Representation (r = 0.47).
 The following significant associations among the 
IPQS subscales and validity measures persisted after 
controlling for inflated   errors due to multiple correla-
tions by conducting regression analyses ( table 5 ): a stron-
ger attribution of present symptoms to mental health 
problems ( Identity ) was associated with more awareness 
of the mental disorder (  = 0.37, p = 0.003) and its social 
consequences (  = 0.25, p = 0.016) according to the clini-
cians’ perspective (SUMD). The perception of a more 
chronic and cyclical timeline was related to higher levels 
of insight assessed by patients’ ratings (IS;   = 0.35, p = 
0.001, respectively   = 0.21, p = 0.040) and, additionally, 
to more positive beliefs about the prescribed medication 
with regard to its necessity (  = 0.22, p = 0.018, respec-
tively   = 0.22, p = 0.025). More perceived negative con-
sequences of the mental health problems were associated 
with less subjective well-being (  = –0.39, p  ! 0.001) and 
more concerns about the prescribed medication (  = 
0.27, p = 0.005). Higher levels of self-blame were linked 
to lower levels of insight into the negative consequences 
of the illness according to clinicians’ ratings (SUMD; 
  = 0.18, p = 0.046). A stronger belief in treatment control 
was associated with lower levels of general psychopathol-
ogy (  = –0.20, p = 0.041), higher levels of subjective well-
being (  = 0.36, p = 0.001), higher levels of insight ac-
cording to patients’ ratings (IS;   = 0.22, p = 0.029) and 
more positive beliefs about the prescribed medication 
(  = 0.32, p  ! 0.001). A stronger sense of illness coher-
ence was linked to higher levels of subjective well-being 
(  = –0.36, p = 0.002). Finally, a stronger emotional re-
sponse to the mental health problems was related to low-
er levels of subjective well-being (  = –0.40, p  ! 0.001), 
higher levels of insight according to patients’ ratings (IS; 
  = 0.22, p = 0.017) and more concerns about the pre-
scribed medication (  = 0.20, p = 0.041). The validity 
measures explained between 3 and 49% of the variance 
of the IPQS subscales.
Table 2.  Inter-subscale correlationsa for the IPQS
I dentityb Timeline
acute/chronic
(n = 128)
Timeline 
cyclical
(n = 128)
Conse-
quences
(n = 128)
Personal
control
(n = 128)
Personal
blame
(n = 128)
Treatment
control
(n = 128)
Illness
coherencec
(n = 128)awareness
(n  = 110)
attribution
(n = 92)
Timeline acute/chronic –0.30** –0.37**
Timeline cyclical –0.18 –0.26* 0.43**
Consequences –0.33** –0.27** 0.38** 0.47**
Personal control 0.01 –0.24* 0.01 0.16 0.09
Personal blame 0.01 0.25* –0.12 0.14 0.07 0.08
Treatment control –0.08 –0.20 0.12 0.23** –0.16 0.32** 0.01
Illness coherencec –0.03 –0.00 0.21* 0.12 0.23** –0.29** 0.22* –0.36**
Emotional representation –0.27** –0.17 0.40** 0.42** 0.67** –0.04 0.21* –0.16 0.46**
a P earson’s correlation (r).
b Higher scores indicate lower awareness of symptoms, respectively, lower attribution to mental health problems.
c Higher scores denote less coherent understanding of the mental health problems.
* p < 0.05; ** p < 0.01.
Table 3.  Test-retest reliability based on a 4-week test interval
IPQS subscale Correlations (r)a Differences (T)b
Timeline acute/chronic 0.70* 0.38
Timeline cyclical 0.63* 0.72
Consequences 0.71* 0.54
Personal control 0.49* 0.53
Personal blame 0.63* 0.72
Treatment control 0.63* 0.34
Illness coherencec 0.65* 0.14
Emotional representation 0.73* –0.81
a  Pearson’s correlation.
b t test score.
c Higher scores denote less coherent understanding of the 
mental health problems.
* p < 0.05.
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Table 4.  Correlationsa between the IPQS subscales and subscales of the PANSS, SWN-K, CDSS, BDI, IS, SUMD and BMQ
Identityb Timeline 
acute/
chronic
(n = 128)
Timeline
cyclical
(n = 128)
Conse-
quences
(n = 128)
Personal 
control
(n = 128)
Personal
blame
(n = 128)
Treat-
ment
control
(n = 128)
Illness 
coher-
 encec
(n = 128)
Emotional
represen-
tation
(n = 128)
awareness
(n = 110)
a ttribution
(n = 92)
PANSS positive syndrome 0.06 0.26* 0.03 0.02 0.13 –0.30** 0.17 –0.24** 0.17 0.23*
PANSS negative syndrome 0.06 0.25* 0.02 –0.02 –0.07 –0.25** 0.12 –0.15 0.04 –0.02
PANSS general psychopathology –0.03 0.23* 0.11 0.08 0.17 –0.31** 0.15 –0.38** 0.23** 0.29**
SWN-K total score 0.26** 0.22* –0.33** –0.19* –0.62** 0.15 –0.03 0.34** –0.46** –0.63**
CDSS –0.17 –0.19 0.19* 0.21* 0.26** –0.19* –0.05 –0.08 0.05 0.25**
BDI-II –0.20* –0.20 0.26** 0.28** 0.45** –0.20* 0.02 –0.20* 0.36** 0.47**
IS total score –0.41** –0.46** 0.47** 0.32** 0.24** 0.11 –0.04 0.35** 0.11 0.29**
SUMD illnessd 0.45** 0.61** –0.28** –0.12 –0.15 –0.16 0.12 –0.20* 0.03 –0.06
SUMD medicationd 0.37** 0.51** –0.21* –0.11 –0.15 –0.12 0.08 –0.30** –0.05 –0.15
SUMD consequencesd 0.47** 0.58** –0.23** –0.12 –0.24** –0.15 0.18* –0.18* 0.04 –0.20*
BMQ specific necessity –0.26** –0.33** 0.38** 0.28** 0.03 0.01 –0.10 0.47** 0.01 0.03
BMQ specific concerns –0.10 0.04 0.01 0.18* 0.53** –0.05 0.09 –0.34** 0.31** 0.47**
BMQ general overuse 0.00 0.19 –0.04 0.05 0.31** –0.02 0.10 –0.44** 0.18* 0.23**
BMQ general harm 0.01 0.28** –0.16 –0.07 0.25** –0.14 0.12 –0.52** 0.16 0.24**
PA NSS = Positive and Negative Syndrome Scale; SWN-K = Subjective 
Well-being under Neuroleptic treatment scale – short form; CDSS = Calgary 
Depression Rating Scale for Schizophrenia; BDI-II = Beck’s Depression In-
ventory-Revised; IS = Insight Scale; SUMD = Scale to Assess Unawareness 
of Mental Disorder; BMQ = Beliefs about Medicines Questionnaire.
a Pearson’s correlation (r). b Higher scores indicate lower awareness 
of symptoms, respectively, lower attribution to mental health problems. 
c Higher scores denote less coherent understanding of the mental health 
problems. d Higher scores indicate lower insight.
* p < 0.05; ** p < 0.01.
Table 5.  Predictive validity of the IPQS subscalesa
Predictor variables I dentityb Timeline
acute/
chronic
(n = 128)
Timeline
cyclical
(n = 128)
Conse-
quences
(n = 128)
Personal
control
(n = 128)
Personal 
blame
(n = 128)
Treat-
ment
control
(n = 128)
Illness 
cohe-
rencec
(n = 128)
Emotional
represen-
tation
(n = 128)
awareness
(n = 110)
attribut ion
(n = 92)
PANSS positive syndrome 0.08 –0.19 0.09 0.12
PANSS negative syndrome 0.15 –0.14
PANSS general psychopathology –0.03 –0.09 –0.20* 0.08 0.02
SWN-K total score 0.14 0.14 –0.19 0.14 –0.39*** 0.36** –0.36** –0.40***
CDSS 0.13 0.17 0.06 –0.07 0.04
BDI-II 0.00 0.03 0.18 –0.00 –0.07 0.02 0.06 –0.01
IS total score –0.14 –0.01 0.35** 0.21* 0.10 0.22* 0.22*
SUMD illnessd 0.21 0.37** –0.11 0.20
SUMD medicationd –0.05 –0.04 0.12 –0.06
SUMD consequencesd 0.24 0.25* 0.06 –0.10 0.18* –0.08 –0.03
BMQ specific necessity –0.04 0.01 0.22* 0.22* 0.32***
BMQ specific concerns 0.17 0.27** 0.10 0.09 0.20*
BMQ general overuse 0.12 –0.14 –0.01
BMQ general harm 0.15 –0.06 –0.14 –0.04 0.05
R2 0.29 0.48 0.33 0.22 0.47 0.15 0.03 0.49 0.23 0.48
PAN SS = Positive and Negative Syndrome Scale; SWN-K = Subjective 
Well-being under Neuroleptic treatment scale – short form; CDSS =
Calgary Depression Rating Scale for Schizophrenia; BDI-II = Beck’s
Depression Inventory-Revised; IS = Insight Scale; SUMD = Scale to As-
sess Unawareness of Mental Disorder; BMQ = Beliefs about Medicines 
Questionnaire. 
a Values between dependent and independent variables are standard-
ized  coefficients. b Higher scores indicate lower awareness of symptoms, 
respectively, lower attribution to mental health problems. c Higher scores 
denote less coherent understanding of the mental health problems. d High-
er scores indicate lower insight.
* p < 0.05; ** p < 0.01; *** p < 0.001.
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 Discussion 
 Summary and Implications 
 In summary, the present results indicate that the ana-
lysed German version of the IPQS has acceptable psycho-
metric properties regarding internal consistency, test-re-
test reliability and construct validity in the majority of 
subscales. While its adequacy for usage with inpatients 
suffering from schizophrenia or schizoaffective disorder 
has already been demonstrated  [20] , the present results 
suggest that the IPQS also adequately assesses outpa-
tients’ IP.
 The individuals examined generally perceived their 
mental health problems as being chronic and cyclical, 
with many negative consequences for their life. Most 
people believed that they have some control over their 
illness and that treatment could help. They blamed 
themselves to a fair degree for their difficulties and ex-
perienced some negative emotions with regard to their 
mental health problems. They estimated the under-
standing of their mental health problems as rather inco-
herent. The subscales’ mean scores were comparable 
with those reported for the English scale version  [20] . 
With regard to beliefs about the causes of the mental 
health problems, we found ‘stress and worry’ to be the 
most accepted causal item. This result is also in line with 
Lobban et al.’s  [20] work and is consistent with the stress 
vulnerability model of schizophrenia; the most widely 
accepted framework of psychosis  [45] . However, it is 
highly relevant that items assessing factors which may 
contribute to the biological vulnerability proposed by 
the model (e.g. ‘hereditary’ or ‘chemical imbalance in 
the brain’) were not judged as relevant for illness causa-
tion in the present sample. This may indicate that our 
predominant strategy in psycho-education programs to 
highlight the biological vulnerability does not reach the 
majority of patients.
 With regard to reliability, the majority of subscales 
demonstrated acceptable levels of internal consistency. It 
is possible that  Personal Blame ,  Personal Control , and  Ill-
ness Coherence did not reach the critical value of   = 0.70 
due to the small number of items and the low correlations 
among them (r s = 0.18–0.26). The reliability scores of  Per-
sonal Blame and  Personal Control had also been insuffi-
cient in the original English scale version  [20] . The sig-
nificant but moderate correlations (r  ! 0.70) between the 
subscales (r = 0.22–0.67), which are comparable to the 
range of inter-subscale correlations reported by the orig-
inal authors  [20] , indicate that they measure distinct di-
mensions of IP and are largely independent of each other. 
Similar to the original scale  [20] , test-retest reliability for 
the German version was high for all subscales, indicating 
good stability over time.
 In sum, with regard to validity, the pattern of correla-
tions found between the IPQS subscales and the mea-
sures of symptoms, depression, beliefs about medication 
and insight denotes adequate construct validity of the 
German version of the IPQS.
 The present study is the first to examine the relation-
ships between measures of insight and the IPQS sub-
scales. The high correlations between the insight mea-
sures (IS, SUMD) and the  Identity  subscale (r = 0.37–0.61) 
may indicate that  Identity assesses a component of IP 
which strongly overlaps with the insight construct. How-
ever, in contrast to our hypothesis the correlation coef-
ficients failed to reach the critical value for convergent 
validity ( 1 0.70). The correlation coefficients between the 
insight measures and the other IPQS subscales were con-
siderably lower (r = 0.18–0.47), indicating that IP exceeds 
the insight construct in several ways (e.g. anticipated 
course of illness or expected controllability) and should 
therefore also be assessed in patients with low insight. In 
our opinion, the results indicate that the IP construct as-
sesses the patients’ point of view in a more comprehensive 
way than the insight construct, thus enabling clinicians 
to adopt treatment approaches of patients with schizo-
phrenia to their individual needs. However, one result re-
garding the relationships between insight and dimen-
sions of IP appeared to be contradictory, at least at first 
glance: while overall, measures of insight were not associ-
ated with the  Personal Blame subscale, being more aware 
of the social consequences of having a mental disorder 
(SUMD subscale) correlated significantly with lower lev-
els of personal blame. It is possible that by becoming 
aware of negative social consequences of the mental dis-
order, one begins to recognize that illness and recovery 
do not occur in a social vacuum but through the dynam-
ic interplay between the individual and his/her environ-
ment  [46] . Such a perception is self-protective and may 
result in lower self-blame. However, given the inadequate 
internal consistency of the  Personal Blame subscale (  = 
0.51) and the fact that only one single insight variable was 
significantly associated with the subscale, the result 
should probably be regarded as a methodological arte-
fact.
 We found a significant positive association between 
the  Specific Necessity subscale of the BMQ and the  Treat-
ment Control subscale of the IPQS. Lobban et al.  [20] 
also reported a positive correlation between  Treatment 
Control and the measure of attitudes towards medica-
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tion (Drug Attitude Inventory, DAI). While positive be-
liefs about the prescribed medication have been shown 
to promote compliance with antipsychotic medication, 
negative beliefs seem to weaken it  [40] . Thus, the present 
result suggests that medication compliance may be 
greater in people who believe that the pharmacological 
treatment will help them to control their illness. Addi-
tionally, the significant positive correlation between the 
 Specific Concerns subscale of the BMQ and the  Negative 
Consequences subscale of the IPQS may indicate that 
negative effects of antipsychotic medication on different 
aspects of interpersonal attractiveness, e.g. feeling re-
duced to the role of the patient by daily medication in-
take or experiencing stigmatizing side effects like im-
mense weight gain, may contribute to medication non-
adherence. Even if these relationships are currently of 
speculative nature and require further investigation, 
they support the idea of IP as a worthwhile predictor of 
compliance behaviour in patients with schizophrenia.
 In contrast to the original study  [20] , the inclusion of 
both patient-rated and clinician-rated validity measures 
in our study enabled us to analyse differences in their as-
sociations with the IPQS subscales. For example, accord-
ing to the patients’ rating (BDI), but not according to the 
clinicians’ rating (CDSS), feeling more depressed was 
linked to a stronger awareness of symptoms  (Identity) – a 
main element of the insight-construct – as well as to less 
belief in treatment control. Because the causal relation-
ship remains unclear due to the correlational analyses 
and cross-sectional nature of data, this result may be in-
terpreted as preliminary evidence for both the idea that 
insight into one’s mental illness and its consequences can 
have a demoralizing effect, as well as the hypothesis that 
depression causes people to evaluate their world more re-
alistically, resulting in better insight  [9] . In our research 
group, we found evidence for the first assumption by 
demonstrating that insight is associated with demoral-
ization, mediated by less belief in treatment control  [47] . 
Taken together, the different associations of patient- and 
clinician-rated measures with the IPQS subscales indi-
cate the benefit of considering both subjective and objec-
tive variables in order to understand a patient’s individu-
al illness model.
 Limitations and Conclusion 
 The present results are restricted by the following lim-
itations: in our study, we decided to ask for awareness of 
symptoms and their attribution to mental health prob-
lems  (Identity) only if a symptom was judged to be actu-
ally present by a clinician. This time-saving strategy was 
chosen to reduce patient burden which may arise if a full 
list of symptoms common to occur in schizophrenia is 
presented (58 symptoms in the original English scale ver-
sion). Additionally, misattribution may only be meaning-
fully judged if there are symptoms present which the pa-
tient could misattribute. Otherwise, this strategy pre-
vented the uncovering of differences in clinicians’ and 
patients’ views of exceptional experiences as belonging to 
mental health problems, because patients were allowed to 
evaluate only those symptoms which had been confirmed 
by clinicians. A further disadvantage of the applied strat-
egy is that the results based on the German IPQS version 
are comparable to those based on the original English 
version – in all subscales except for  Identity . Additionally, 
because we assessed the Identity subscale only once, we 
were not able to establish its test-retest reliability. Fur-
thermore, the proposed structure of the IPQS has not 
been examined so far. For this purpose, further studies 
are needed which should preferably use confirmatory 
factor analysis, as it has been done for the IPQ for physi-
cal illnesses  [17, 48, 49] .
 Nevertheless, the present results may encourage the 
use of the German version of the IPQS (especially both 
 Timeline ,  Consequences ,  Treatment Control , and  Emo-
tional Representation subscales) in further studies inves-
tigating the impact of subjective beliefs about mental 
health problems on outcome variables such as illness and 
treatment course, or compliance behaviour in patients
diagnosed with a schizophrenia spectrum disorder.
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